PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial

Abstract Background Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people older than 50, resulting in pain and stiffness of the neck, shoulder, and pelvic girdle. To date, glucocorticoids (GC) remain the cornerstone of treatment, but these have several drawbacks. Firstly...

Full description

Bibliographic Details
Main Authors: Diane E. Marsman, Thomas E. Bolhuis, Nathan den Broeder, Alfons A. den Broeder, Aatke van der Maas
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Trials
Subjects:
Polymyalgia rheumatica
Early disease
Methotrexate
Glucocorticoid sparing
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-022-06263-3

Internet

https://doi.org/10.1186/s13063-022-06263-3

Similar Items